Genomic heart disease drug developer Verve Therapeutics secured funding in a round led by GV, which also led its series A last year.

GenScript Biotech's spinoff Legend Biotech, which counts Eli Lilly and Johnson & Johnson as backers, floated in the US.

The emergency response software provider, which counts AAA, CSAA, Microsoft and Motorola Solutions as investors, lifted its total funding to $107m.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Remote care platform developer Conversa increased its total funding to more than $26m in a round co-led by Northwell Ventures and backed by UH Ventures.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

AstraZeneca and Fresenius Medical Care will exit the kidney disease treatment developer in a $725m acquisition that could potentially rise to $2.1bn.

Novo co-led the series C round with Longitude Capital and Checkmate will use the cash to advance clinical development of its lead asset, which is targeting melanoma.

Based on research at University of Adelaide, Royal Adelaide Hospital and Johns Hopkins's Hospital, Glyscend is working on a pill to treat type 2 diabetes.

UCeed will target four to eight healthcare projects with a focus on child medicine, investing up to $220,000 per transaction.